Form 4: Red Violet CEO Sells 15,000 Shares Under 10b5-1 Plan
Insider Transaction Report
Red Violet's CEO and Chairman, Derek Dubner, reported the sale of 15,000 shares of common stock between November 10 and November 13, 2025, pursuant to a Rule 10b5-1 plan.
Summary
- Derek Dubner, the Chief Executive Officer, Chairman of the Board, Director, and a 10% owner of Red Violet, Inc. (RDVT), reported multiple sales of common stock.
- A total of 15,000 shares of common stock were sold in a series of transactions between November 10, 2025, and November 13, 2025.
- The sales were executed at weighted average prices ranging from $56.73 to $58.81 per share.
- These transactions were made pursuant to a Rule 10b5-1(c) plan, indicating they were pre-scheduled.
- Following these sales, Dubner's direct beneficial ownership stands at 556,000 shares of common stock.
- The beneficial ownership of 556,000 shares includes 26,666 Restricted Stock Units (RSUs) granted on November 30, 2023, vesting in two equal installments on December 1, 2025, and December 1, 2026.
- It also includes 21,000 RSUs granted on November 4, 2024, vesting in two equal installments on November 1, 2026, and November 1, 2027.
Sentiment
Score: 5
Explanation: The sales by CEO Derek Dubner, while reducing his direct beneficial ownership, were conducted under a pre-arranged Rule 10b5-1 plan. This mitigates the negative signal typically associated with insider selling, as the transactions were not based on recent discretionary decisions.
Negatives
- The reduction in direct beneficial ownership by a key executive, even if pre-planned, can be perceived by some investors as a decrease in insider alignment with shareholder interests.
Future Outlook
The filing does not provide a future outlook for the company's performance, focusing solely on insider transactions.
Industry Context
This insider transaction report does not provide specific industry context, but insider selling is a common occurrence across various industries, often for personal financial planning or diversification.
Stakeholder Impact
- Shareholders may view the reduction in the CEO's direct beneficial ownership with caution, even if the sales were pre-planned, as it represents a decrease in direct equity alignment.
Next Steps
- The remaining Restricted Stock Units (RSUs) held by Derek Dubner are scheduled to vest in installments on December 1, 2025, December 1, 2026, November 1, 2026, and November 1, 2027.
Key Dates
| Date | Description |
|---|---|
| 2023-11-30 | Grant date for 26,666 RSUs to Derek Dubner. |
| 2024-11-04 | Grant date for 21,000 RSUs to Derek Dubner. |
| 2025-11-10 | Earliest transaction date for common stock sales by Derek Dubner. |
| 2025-11-11 | Transaction date for common stock sales by Derek Dubner. |
| 2025-11-12 | Transaction date for common stock sales by Derek Dubner. |
| 2025-11-13 | Latest transaction date for common stock sales by Derek Dubner and filing date of the Form 4. |
| 2025-12-01 | First vesting installment for 26,666 RSUs granted on November 30, 2023. |
| 2026-11-01 | First vesting installment for 21,000 RSUs granted on November 4, 2024. |
| 2026-12-01 | Second vesting installment for 26,666 RSUs granted on November 30, 2023. |
| 2027-11-01 | Second vesting installment for 21,000 RSUs granted on November 4, 2024. |
Recommendation
holdThe sales by CEO Derek Dubner were executed under a Rule 10b5-1 plan, which suggests the transactions were pre-scheduled and not indicative of a sudden loss of confidence. While the reduction in direct beneficial ownership by a key executive is noted, the pre-planned nature of the sales supports a 'hold' recommendation rather than a 'sell', as it doesn't necessarily signal new negative developments.
Keywords
Red Violet, RDVT, Insider Trading, Form 4, Stock Sale, Derek Dubner, CEO, Director, Chairman, Equity Transaction, 10b5-1 Plan, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.